FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381112910> ?p ?o ?g. }

• W4381112910 abstract "<h3>Introduction</h3> Vedolizumab (VDZ), a gut selective anti-lymphocyte trafficking anti-α₄β₇ integrin monoclonal antibody indicated for the treatment of inflammatory bowel disease (IBD). After a 3 dose intravenous (IV) induction, maintenance can be achieved with a standard 8-weekly (Q8W) IV regimen, or-at any time during the maintenance- patients can be transitioned to 108 mg subcutaneous (SC) formulation at a standard 2 weekly (Q2W) regimen. <h3>Methods</h3> A literature review was conducted to identify real-world studies on the transition from IV to SC VDZ. The Pubmed and Embase databases were searched up to October 2022 to identify publications on real-world data on the transition from IV to SC VDZ. <h3>Results</h3> In total, 9 studies were identified with a total of 1,323 IBD patients in the UK (5 studies), Norway, Sweden, Belgium and The Netherlands.^1–9 Two prospective studies reported no loss of effectiveness based on disease activity scores of VDZ after the IV to SC transition,^{1 2} along with maintenance of baseline status (status at the time of transition) reported in 84% of patients.¹ Biomarkers stability, including fecal calprotectin and C-reactive protein, were reported in three studies.^3–5 Persistence with VDZ treatment following IV-SC transition was 96% at 6 months and 89% at 12 months in one study,³ while another study reported persistence of 86% at 6 months.⁶ A preference for the SC formulation by patients was reported 59% and 56% in two studies,^{7 8} with time savings and fewer hospital visits recorded as the main reasons for preference of the SC formulation.⁷ Multivariate analysis of patient characteristics in two studies^{7 8} revealed no factor associated with preference for VDZ SC other than younger age in one study.⁸ The most frequently reported adverse events with VDZ SC were injections site reactions: 15% and 18% in two studies,^{1 5} with transient severe injection site reactions reported in 1% of patients in one study.³ <h3>Conclusions</h3> Real-world data on IBD patients who transitioned from IV to SC VDZ showed no change in effectiveness, with studies showing a majority preferring the SC formulation with time savings and the transition leading to fewer hospital visits identified as reasons for preference in one study. Safety of VDZ SC was generally comparable with that of IV VDZ. <h3>References</h3> Ventress E, <i>et al J Crohn’s Colitis</i> 2022;<b>16</b>:911–21. Volkers A, <i>et al Aliment Pharmacol Ther</i> 2022;<b>56</b>:1044–54. Bergqvist V, <i>et al Aliment Pharmacol & Ther</i> 2022;<b>55</b>:1389–1401. Mclean M, <i>et al Gut</i> 2022;<b>71</b>:A58-A59. Wiken T, <i>et al J Crohn’s Colitis</i> 2022;<b>16</b>:i378–79. Lim S, <i>et al J Crohn’s Colitis</i> 2022;<b>16</b>:i499-i500. Alice H, <i>et al J Crohn’s Colitis</i> 2022;<b>16</b>:i410. Asnong K, <i>et al J Crohn’s Colitis</i> 2022;<b>15</b>:S608–9. Maw F, <i>et al. Gut</i> 2021;<b>70</b>:a91." @default.
• W4381112910 created "2023-06-19" @default.
• W4381112910 creator A5017359233 @default.
• W4381112910 creator A5045509681 @default.
• W4381112910 creator A5053492143 @default.
• W4381112910 date "2023-06-01" @default.
• W4381112910 modified "2023-09-27" @default.
• W4381112910 title "P105 Real world experience of the transition from intravenous to subcutaneous formulation of vedolizumab in inflammatory bowel disease: current data review" @default.
• W4381112910 doi "https://doi.org/10.1136/gutjnl-2023-bsg.177" @default.
• W4381112910 hasPublicationYear "2023" @default.
• W4381112910 type Work @default.
• W4381112910 citedByCount "0" @default.
• W4381112910 crossrefType "proceedings-article" @default.
• W4381112910 hasAuthorship W4381112910A5017359233 @default.
• W4381112910 hasAuthorship W4381112910A5045509681 @default.
• W4381112910 hasAuthorship W4381112910A5053492143 @default.
• W4381112910 hasConcept C126322002 @default.
• W4381112910 hasConcept C2776207728 @default.
• W4381112910 hasConcept C2778260677 @default.
• W4381112910 hasConcept C2779134260 @default.
• W4381112910 hasConcept C2781413609 @default.
• W4381112910 hasConcept C71924100 @default.
• W4381112910 hasConcept C90924648 @default.
• W4381112910 hasConceptScore W4381112910C126322002 @default.
• W4381112910 hasConceptScore W4381112910C2776207728 @default.
• W4381112910 hasConceptScore W4381112910C2778260677 @default.
• W4381112910 hasConceptScore W4381112910C2779134260 @default.
• W4381112910 hasConceptScore W4381112910C2781413609 @default.
• W4381112910 hasConceptScore W4381112910C71924100 @default.
• W4381112910 hasConceptScore W4381112910C90924648 @default.
• W4381112910 hasLocation W43811129101 @default.
• W4381112910 hasOpenAccess W4381112910 @default.
• W4381112910 hasPrimaryLocation W43811129101 @default.
• W4381112910 hasRelatedWork W2327744141 @default.
• W4381112910 hasRelatedWork W2328584717 @default.
• W4381112910 hasRelatedWork W2660092592 @default.
• W4381112910 hasRelatedWork W2802584626 @default.
• W4381112910 hasRelatedWork W3002872293 @default.
• W4381112910 hasRelatedWork W3166003727 @default.
• W4381112910 hasRelatedWork W3209514756 @default.
• W4381112910 hasRelatedWork W4230207006 @default.
• W4381112910 hasRelatedWork W4254838536 @default.
• W4381112910 hasRelatedWork W4360619954 @default.
• W4381112910 isParatext "false" @default.
• W4381112910 isRetracted "false" @default.
• W4381112910 workType "article" @default.